Biotech & Medicine
Cruciform resurrection parasite
A symbiont embedded in the body that rebuilds its host from scratch after death, with each resurrection eroding intelligence and memory.
In shortCruciform resurrection parasite, from Hyperion (Dan Simmons, 1989), is at technology readiness level 1 of 9 (basic principles observed) at its weakest link. Held back by Cell-by-cell in-vivo repair and Desktop molecular assembler. Science status: consistent with known physics; key effects unproven at scale. Estimated new funding to unlock: $20B–162B (a floor; some parts are priced only to early research).
In the Priest's Tale, Father Hoyt and Father Duré find the Bikura, who are kept alive indefinitely by cross-shaped cruciform parasites that rebuild their bodies after each death but leave them dull and childless.
Closest todayRegeneration in axolotls and planarians, and Turritopsis jellyfish reverting to a juvenile stage; nothing rebuilds a whole mammal.
Dependency stack
Research TRL 1–3Development TRL 4–6Deployment TRL 7–9
Sort by
- Reconstructing a dead body requires directed repair at every cell
- No way to read the internal state of a living cell without destroying it
- A human body has roughly 3x10^13 cells, so any per-cell procedure needs a throughput no proposed system approaches
- Molecular-scale positional control in a warm, crowded, aqueous environment is unsolved
- Energy supply and waste handling for billions of simultaneously operating devices is unaddressed
plausibleTRL 1- Desktop molecular assemblerbottleneckRebuilding damaged structures implies atomically precise construction under program control
- Requires positional mechanosynthesis at ~10^6 operations/s per tool and ~10^9 parallel tools
- Heat dissipation and error correction for atomically precise assembly at kilogram scale
- No bootstrap path from today's scanning probes to self-built nanoscale tools
plausibleTRL 1- The basic operation the assembler repeats billions of times
✕3 blockers›
- Tool-tip reactions are cryogenic, UHV and succeed probabilistically; no reaction set with >99.9% per-step fidelity
- No demonstrated tooltip recharge cycle, so each tip makes only a handful of bonds
- Throughput of ~1 operation per minute is ~20 orders of magnitude short of bulk manufacturing
plausibleTRL 2 - Most credible bootstrap path is self-assembling designed protein machinery that positions reactants
✕1 blocker›
- Designing catalysis and conformational dynamics
TRL 6
- Repair requires devices that sense and act inside tissue, not just circulate
✕4 blockers›
- No onboard power source or computation - behavior is limited to a single preset molecular trigger
- Immune clearance and protein-corona formation remove most devices within hours
- Actuation cannot overcome blood flow or cross tissue barriers on command
- External actuation rigs used in labs do not fit clinical imaging suites
TRL 3- Nucleic-acid scaffolds are the only programmable construction material at this scale today
✕3 blockers›
- Nuclease degradation and cation-dependent unfolding limit in-vivo lifetime to hours without protective coatings
- Structures generate piconewton forces - far below what mechanical work on cells would need
- No onboard logic beyond a handful of strand-displacement states
TRL 5 - A device you cannot localize in the body cannot be steered or verified
✕3 blockers›
- Optical scattering caps high-resolution imaging at a few millimetres of tissue depth
- MRI gives depth but not video-rate cell-scale resolution, and excludes magnetic actuation hardware
- Tracking swarms rather than single objects has no demonstrated method
TRL 5 - Sensing and effector modules are designed proteinsTRL 6
- Repair must be verified in place, not inferred from outcomesTRL 5
- The cruciform itself is a sensing, decision-making agent operating inside tissueTRL 3
- Rebuilt organs need a functioning blood supply
✕4 blockers›
- Capillary-scale perfusion cannot be printed and must self-assemble, which is uncontrolled today
- Printed tissue must mature into function (filtration, metabolism, contraction), and maturation protocols stall at fetal-like performance
- Cell demand of 10^10-10^11 per organ exceeds current manufacturing
- Mechanical integration - ureters, bile ducts, valves - has no demonstrated fabrication route
TRL 4- Without a capillary network, tissue thicker than a few hundred microns dies
✕3 blockers›
- Printing resolution stops at tens of microns while capillaries are 5-10 microns, so the smallest and most numerous vessels must self-assemble
- Engineered endothelium is thrombogenic, so perfused constructs clot
- No method guides anastomosis of a construct's vasculature to host vessels at scale
TRL 3 - Banked-cell organs are not patient-matched, so acceptance must be engineered
✕3 blockers›
- Chronic antibody-mediated rejection proceeds even under current immunosuppression
- Tolerance protocols trade rejection risk for conditioning toxicity and graft-versus-host disease
- No assay predicts which recipients can be safely weaned off drugs
TRL 5 - One organ needs 10^10-10^11 clinical-grade cells of several types
✕3 blockers›
- Genomic instability and drift accumulate over the expansion needed for 10^11 cells
- Each organ needs many cell types differentiated on a synchronized schedule, not one lineage
- Cost per cell at current media and reagent prices makes a printed organ unaffordable
TRL 6
- supportingSynapse-level whole-brain preservationThe depicted memory loss is exactly what happens when brain structure is not preserved through death
✕3 blockers›
- Ischemic damage starts within minutes of circulatory arrest, before perfusion can begin
- Aldehyde fixation may destroy molecular state (phosphorylation, receptor conformation) that could carry memory
- No assay proves preserved tissue still contains the information an emulation would need
TRL 4
Who could unlock it
- Across several requirements:
- Bradley Nelson 2
- Hao Yan 2
- Bionaut Labs 2
Cell-by-cell in-vivo repairTRL 1bottleneck
- Wei GaoResearcher, California Institute of TechnologyBuilt bioresorbable acoustic microrobots that were ultrasound-tracked and magnetically steered to shrink bladder tumours in mice (Science Robotics, 2024), then simplified them into self-targeting bubble bots (Nature Nanotechnology, February 2026)
- Bjoern HoegbergResearcher, Karolinska InstitutetBuilds DNA origami devices that hide a cytotoxic peptide pattern until a tumour's acidic pH triggers display, killing tumour cells in mice (2024) - the closest thing to a conditional molecular machine acting in a body
- Bradley NelsonResearcher, Multi-Scale Robotics Lab, ETH ZurichLong-running program on magnetically actuated micro- and nanorobots and the control and imaging needed to steer them through real tissue
- Hao YanResearcher, Biodesign Center for Molecular Design and Biomimetics, Arizona State UniversityPioneer of programmable DNA origami architectures, including origami nanostructures used as triggerable drug carriers in animal models
Desktop molecular assemblerTRL 1bottleneck
- Robert FreitasResearcher, Institute for Molecular ManufacturingCo-author of Kinematic Self-Replicating Machines and of theoretical mechanosynthesis toolsets and nanofactory designs
- Ralph MerkleResearcher, Institute for Molecular ManufacturingCo-developed theoretical assembler and mechanosynthesis designs; co-inventor on CBN Nano's mechanosynthesis patents
- CBN Nano TechnologiesStartupOttawa company pursuing experimental tip-based mechanosynthesis as a path to nanofactories; holds Freitas/Merkle patents
- Foresight InstituteProgramNonprofit funding molecular-machine and APM research (~$1.5M grants in 2024) and awarding the Feynman Prizes
Programmable in-vivo nanodevicesTRL 3
- Bjorn HogbergResearcher, Karolinska InstitutetHis pH-triggered DNA-origami nanorobot displaying death-receptor peptides cut breast-cancer xenograft growth by about 70 percent (2024)
- Bradley NelsonResearcher, ETH ZurichSenior author of Clinically ready magnetic microrobots for targeted therapies (Science, November 2025), carrying thrombolytics, antibiotics or tumour drugs and tested in pigs
- Hao YanResearcher, Arizona State UniversityBuilt the thrombin-releasing DNA origami nanorobot that shuts down tumour blood supply, reported immunologically inert in mice and miniature pigs
- Nanoflex RoboticsStartupETH Zurich spin-off commercialising the magnetic navigation hardware needed to steer devices from inside a clinical imaging suite
Biofabrication of vascularized human organsTRL 4
- ARPA-H PRINTProgramAwarded five teams up to 176.8 million dollars over five years in January 2026 to attempt what the agency says has not been done, a human-sized functional printed organ
- Anthony AtalaResearcher, Wake Forest Institute for Regenerative MedicinePrincipal investigator of the award of up to 24.8 million dollars announced January 2026 to produce clinical-grade vascularised renal tissue
- Wyss InstituteAcademic labPRINT awardee engineering universal clinical-scale liver tissue from adult stem cells as an implantable therapy
- Carnegie Mellon UniversityAcademic labPRINT awardee building a cost-effective immune-silent bioprinted liver for acute liver failure, targeting first-in-human within five years
Beyond engineering
- Legal and religious status of a person who has died and been rebuilt
- The depicted trade (immortality for cognitive decline) raises consent questions for anyone not yet infected